UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
__________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 11, 2020
AngioDynamics, Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware
| 000-50761
| 11-3146460
|
| | | |
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
14 Plaza Drive Latham, New York 12110
|
| |
| (Address of Principal Executive Offices) (Zip Code) |
| |
| (518) 795-1400 |
| |
| (Registrant’s telephone number, including area code) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b)) |
| ☐
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which
registered |
| | | |
Common Stock, par value $0.01 per share
| ANGO
| NASDAQ Global Select Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 – Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August 11, 2020, Kevin Gould announced his intention to retire from his position as a director on the Board of Directors of AngioDyanmics, Inc. (the “Company”), effective as of the date of the 2020 annual meeting of shareholders of the Company, which is currently scheduled for October 13, 2020. Mr. Gould’s retirement was not the result of any disagreement between Mr. Gould and the Company on any matter relating to the Company’s operations, policies or practices.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | ANGIODYNAMICS, INC. | |
| | (Registrant)
| |
| | | |
| | | | |
| Date: August 14, 2020 | By: | /s/ Stephen A. Trowbridge | |
| | | Stephen A. Trowbridge | |
| | | Executive Vice President, General Counsel | |
| | | and Chief Financial Officer
| |
